Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2026-01-28 @ 10:53 PM
Study NCT ID:
NCT02982395
Status:
TERMINATED
Last Update Posted:
2019-08-30
First Post:
2016-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Sponsor:
Samyang Biopharmaceuticals Corporation
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non Muscle Invasive Bladder Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Nanoxel M | View |
| None | Docetaxel PM | View |
| None | Docetaxel | View |
| None | Mitomycin C | View |
| None | BCG | View |
| None | BCG refractory | View |
| None | Non muscle invasive bladder cancer | View |
| None | intravesical | View |
| None | superficial bladder cancer | View |
| None | Urothelial carcinoma | View |
| None | Transitional cell carcinoma | View |